News

ASA404 is a tumor-vascular disrupting agent (tumor-VDA). Novartis signed an exclusive licensing agreement with Antisoma for the worldwide rights to ASA404 in April 2007. In March 2010, ASA404

Sage Bionetworks said that a team of network biologists, systems biologists, statistical geneticists and computational biologists use coherent datasets containing clinical, genetic and molecular layers of information to

AOBO is a pharmaceutical company dedicated to improving health through the development, manufacture and commercialisation of prescription and OTC products. AOBO chairman and CEO Tony Liu said that

Lotus Pharma has posted a net income of $6.7m for the third quarter 2010, or $0.12 per diluted share, compared to net income of $5.39m, or $0.11 per

HES is derived from waxy maize starch and can be metabolised by the body’s enzymes. Fresenius Kabi provided Boehringer with its HESylation Technology to manufacture HES conjugated to

Centocor Ortho Biotech said that the sBLA includes inhibition of the progression of structural damage and maintenance of improvement in signs and symptoms and physical function in the

As per the terms of the agreement, Forest is entitled to get an undisclosed signing fee, milestones and sales-related royalties from Janssen Pharmaceutica and Janssen Pharmaceutical, in exchange

The company said that DeltaVision OMX is a super-resolution microscopy system which more than doubles the optical resolution of the traditional light microscope in all three dimensions. The

MedQuist is a provider of integrated clinical documentation solutions for the US healthcare industry. MedQuist’s operating income was $13.29m, compared to $8.12m for the comparable period in 2009.